GuidelineBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2020
Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients.
Guideline in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022).Transplantation and cellular therapy · 2022Guideline
- Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Guideline
- Vaccines for Use in Special Populations: Immunocompromised Hosts.The Journal of infectious diseases · 2025Article
- Hospital-mandated restrictions during the COVID-19 pandemic alter hospital-acquired viral respiratory infections during hematopoietic stem cell transplantation: a single center pediatric experience.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Impact of the COVID-19 outbreak on the field of hematopoietic cell transplantation in the Asia-Pacific region: APBMT Activity Survey 2020/2021.Blood cell therapy · 2024Article
- Comparison of the Clinical Outcomes Between Early and Delayed Transplantation After SARS-CoV-2 Infection.Journal of Korean medical science · 2024Article
- Antibiotic prescribing guideline recommendations in COVID-19: a systematic survey.EClinicalMedicine · 2023Article
- Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic.Blood advances · 2023Article
- The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021.JAMA network open · 2023Observational
- Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial.Oncology and therapy · 2023Article
- Nosocomial COVID-19 at a comprehensive cancer center during the first year of the pandemic: Lessons learned.American journal of infection control · 2023Article
- Successful Autologous Bone Marrow Transplantation in Active COVID-19 Patients: Case Report.Transplantation proceedings · 2023Article
- The impact of COVID-19 on acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: a concise review.Blood research · 2023Review
- Article
- Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study.Frontiers in immunology · 2023Observational
- Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem.Transplantation and cellular therapy · 2022Review
- COVID-19 and HSCT (Hematopoietic stem cell transplant).Best practice & research. Clinical haematology · 2022Review
- Article
- European Respiratory Society statement on long COVID follow-up.The European respiratory journal · 2022Article
- Perceptions and Experiences of Hematopoietic Cell Transplantation Patients During the COVID-19 Pandemic.Seminars in oncology nursing · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
Abstract
There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.